For sale: One Swiss biotech with an antibiotic and a low tax rate

With the FDA insisting on more studies before it will consider approval of its new antibiotic and needing money to pay for them, Switzerland-based Basilea figures it might sell some assets to raise the money. And the assets it has are itself and its EU tax base, Bloomberg reported. And so the Basel-based biotech is offering itself up to any U.S.-based pharma that wants to make what might be called a tit for tax deal. Story